CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Madrigal Pharmaceuticals, Inc.

MDGL
$11.80BLarge Cap

Next catalyst

Phase 3December 2026

Resmetirom

NASH

Get an email about MDGL's next catalysts

Track Madrigal Pharmaceuticals (MDGL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Phase 3Next

Resmetirom Phase 3 Est. Readout

December 2026~Resmetirom845

Primary completion for Resmetirom trial (NCT05500222) in NASH

Source
Phase 3

Resmetirom Phase 3 Est. Readout

March 2027~Resmetirom810

Primary completion for Resmetirom trial (NCT04951219) in Non-Alcoholic Fatty Liver Disease

Source

How MDGL's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaWEST CONSHOHOCKEN528 employees
Drug Pipeline

Frequently asked questions

What is in Madrigal Pharmaceuticals, Inc.'s drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in Madrigal Pharmaceuticals, Inc.'s (MDGL) pipeline across Phase 3, Phase 2. Its lead program is Resmetirom (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Madrigal Pharmaceuticals, Inc.'s next FDA catalyst?β†’

Madrigal Pharmaceuticals, Inc.'s (MDGL) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MDGL biotech catalysts?β†’

Add MDGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Madrigal Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply